NanoVibronix (56R1) Stock Overview
Through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
56R1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NanoVibronix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.55 |
| 52 Week High | US$32.40 |
| 52 Week Low | US$7.70 |
| Beta | 2.18 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.18% |
| 5 Year Change | n/a |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 56R1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -1.4% |
| 1Y | n/a | -0.4% | 12.6% |
Return vs Industry: Insufficient data to determine how 56R1 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 56R1 performed against the German Market.
Price Volatility
| 56R1 volatility | |
|---|---|
| 56R1 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 56R1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 56R1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 31 | Doron Besser | www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures.
NanoVibronix, Inc. Fundamentals Summary
| 56R1 fundamental statistics | |
|---|---|
| Market cap | €4.56m |
| Earnings (TTM) | -€4.10m |
| Revenue (TTM) | €2.00m |
Is 56R1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 56R1 income statement (TTM) | |
|---|---|
| Revenue | US$2.34m |
| Cost of Revenue | US$1.59m |
| Gross Profit | US$750.00k |
| Other Expenses | US$5.55m |
| Earnings | -US$4.80m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.51 |
| Gross Margin | 32.07% |
| Net Profit Margin | -205.26% |
| Debt/Equity Ratio | 4.9% |
How did 56R1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 06:44 |
| End of Day Share Price | 2025/07/09 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NanoVibronix, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.